Pharmalytics

What Pharmalytics does

Pharmalytics is a privately held, GMP-certified contract analytical testing laboratory headquartered in Bayswater, Victoria, Australia, founded in 2019 by Dr. Russell Kinghorn. The company provides pharmaceutical, life science, clinical trial, veterinary, and medicinal cannabis clients with six integrated service lines: medicinal cannabis and cannabinoid testing (including TGO93-compliant assays), ICH stability storage and testing across five standardized conditions plus photostability and freeze/thaw studies, microbiological testing delivered through a partnered TGA-licensed laboratory, GMP method development and validation, research and development support, and BP/EP/USP pharmacopoeial testing. Technical capabilities are anchored by HPLC, uHPLC, LC-MS/MS, GC-MS/MS, and ICP-MS instrumentation supplied through flagship first-to-market partnerships with Agilent Technologies and Mettler Toledo, with all results captured in a fully electronic, database-driven, 21 CFR Part 11 compliant quality management system that the company claims is unique among Australian contract testing facilities.

The business operates on a professional services revenue model, generating income through project-based or contract-based GMP testing engagements priced via custom quotes rather than published rate cards. Go-to-market is exclusively enterprise B2B direct sales, executed through sales consultations, downloadable Analysis Request Forms, and direct phone/email contact, targeting pharmaceutical manufacturers, clinical trial sponsors, veterinary product companies, medicinal cannabis producers, and life science researchers. The laboratory holds TGA licence MI-2019-LI-09504-1, APVMA licence No. 6224, and US FDA registration (FEI: 3016044111), enabling both domestic Australian regulated testing and cross-border GMP testing for clients with US market exposure. Pharmalytics is founder-owned and operated with a small team of 1-10 employees, and there is no evidence of external institutional investment in the available source material.

Name

Pharmalytics

Legal name

Pharmalytics

Website

https://pharmalytics.com.au

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Pharmalytics is an Australian GMP-certified contract analytical testing laboratory founded in 2019, serving pharmaceutical, clinical trial, veterinary, medicinal cannabis, and life science clients with pharmacopoeial testing, ICH stability studies, method validation, and a fully 21 CFR Part 11 compliant electronic quality system.

Ownership category

akta.pro rank

Product category

Contract Pharmaceutical Analytical Testing

NAICS

Testing Laboratories and Services (541380), Testing Laboratories and Services (54138)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Method Development & Validation (ICH/USP) (HLAGADAB)

akta.pro secondary industries

Small-Molecule Analytical Development & Method Validation (CMC) (HLAGAHAF), Release Testing & Batch Certification (QC) (HLAGADAC), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Contract pharmaceutical testing
• GMP analytical testing
• ICH stability storage
• Medicinal cannabis testing
• Microbiological testing services

Headquarters

HQ city

Bayswater

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. GMP Contract Analytical Testing Services: Pharmalytics generates revenue through providing GMP-compliant contract analytical testing services for pharmaceutical, life science, clinical trial, and veterinary industries. Services include pharmacopoeial testing, method development and validation, ICH stability storage and testing, microbiological testing, research and development, and medicinal cannabis/cannabinoid testing. Revenue is likely project-based or contract-based, with clients submitting samples for specific testing requirements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Pharmalytics is a GMP contract analytical testing laboratory providing pharmaceutical, life science, clinical trial, and veterinary clients with pharmacopoeial testing (BP, EP, USP), method development and validation, ICH stability storage and testing, microbiological testing, research and development, and medicinal cannabis/cannabinoid testing. Services are delivered through state-of-the-art chromatographic instrumentation and a fully electronic 21 CFR Part 11 compliant quality management system that is the only one of its kind in an Australian contract GMP laboratory.

Product overview

Pharmalytics offers a single integrated GMP contract analytical testing service for the pharmaceutical, life science, clinical trial, and veterinary industries. The service portfolio is organized into six interconnected service lines: Medicinal Cannabis & Cannabinoids Testing (cannabis flower testing to TGO93, CBD/THC profiling, terpene profiling), ICH Stability Storage & Testing (long-term, intermediate, and accelerated conditions across five standardized conditions plus photostability and freeze/thaw studies), Microbiological Testing (sterile and non-sterile, delivered via a TGA-licensed partner lab with consolidated electronic reporting), Method Development & Validation (GMP-compliant method development, validation, verification, and analytical transfer), Research & Development (specialist assay development, contamination investigations, impurity identifications), and Pharmacopoeial Testing (BP, EP, USP monographs covering raw materials and finished products across physical, chemical, and microbiological disciplines). All services are supported by the company's electronic quality management system, which is the only fully electronic 21 CFR Part 11-compliant system in a contract GMP laboratory in Australia.

Differentiator

Problem solved

Functional benefit

Products and services

• Medicinal Cannabis & Cannabinoids Testing Cannabis flower testing to TGO93 requirements including aflatoxins, ochratoxin A, heavy metals, and pesticides; intermediate CBD and THC resin testing; full spectrum CBD product determination; finished product assays in oils and capsules; comprehensive terpene and cannabinoid profiles; stability studies to ICH guidelines. Targeted at medicinal cannabis and cannabinoid product manufacturers in Australia.
• ICH Stability Storage & Testing Full suite of long-term, intermediate and accelerated stability conditions (2–8°C, 25°C/60% RH, 30°C/65% RH, 30°C/75% RH, 40°C/75% RH) with validated stability chambers, 24/7 electronic environmental monitoring, photostability trials, and freeze/thaw studies. Targeted at pharmaceutical, clinical trial, and veterinary manufacturers requiring ICH-compliant stability programs.
• Microbiological Testing Full suite of non-sterile and sterile microbiological testing options, delivered in partnership with a TGA-licensed microbiological laboratory, with full electronic reporting consolidated into a single comprehensive report. Targeted at pharmaceutical, clinical trial, and veterinary product manufacturers requiring microbiological quality control.
• Method Development & Validation Method development and validation services including forced degradation / stability-indicating validations, verification of pharmacopoeial methods, analytical transfer, and extractable/leachable study design and testing. Targeted at pharmaceutical manufacturers, clinical trial sponsors, and development-stage companies requiring GMP-compliant analytical methods.
• Research & Development

Quantifiable outcome

• Results down to the 5th decimal place precision

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• Agilent TechnologiesflagshipTechnology or IntegrationPharmalytics is a first-to-market partner for Agilent Technologies, a global leader in the supply of instruments, services and consumables for life sciences, diagnostics and applied chemical markets. Agilent's end-to-end portfolio enables reliable, precise answers for all stages of a product's lifecycle and ensures excellence, optimal performance and robustness for Pharmalytics at all times.
• Mettler ToledoflagshipTechnology or IntegrationPharmalytics is a first-to-market partner for Mettler Toledo, renowned worldwide for the accuracy of their precision instruments. Their instruments combined with LabX software fully support current requirements of regulatory bodies including TGA and FDA under a 21 CFR Part 11 compliant framework, enabling Pharmalytics to deliver innovations in performance, measurement techniques and evaluation procedures.
• TGA Licensed Microbiological LaboratorycoreStrategic or Co-development PartnerPharmalytics partners with an industry leading TGA licensed microbiological laboratory for comprehensive microbiological testing services. All samples are fully validated and include full electronic reporting. Testing performed by Pharmalytics and the microbiological lab site is combined into a single, comprehensive report.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• ALS Limited: ALS is an Australia-headquartered global testing services group with pharmaceutical and life-sciences testing capacity alongside environmental, food, and minerals labs; it competes with Pharmalytics in pharma analytical services but as part of a much broader portfolio.
• Bureau Veritas Pharmaceutical Services: Bureau Veritas operates a global pharmaceutical and life-sciences testing network covering GMP analytical services, stability, and method validation; it serves Australian customers through regional hubs as another large incumbent against Pharmalytics.
• Eurofins BioPharma Product Testing: Eurofins' BioPharma division is the largest global pharmaceutical contract testing network; it operates GMP analytical labs in Australia and competes directly with Pharmalytics for method validation, stability, and release testing work, though it offers a far broader portfolio and consolidates across geographies.
• Element Materials Testing (Life Sciences): Element is a global testing and certification group that includes pharmaceutical and life-sciences testing services; it competes with Pharmalytics for pharma analytical work but as part of a very broad industrial testing portfolio.
• Intertek Pharmaceutical Services: Intertek is a global TIC provider with pharmaceutical stability, method validation, and release testing capabilities serving Australian and international clients; it overlaps directly with Pharmalytics' core service offering but operates at significantly greater scale.
• Thermo Fisher Scientific (Pharma Services): Thermo Fisher's PPD and Patheon-adjacent pharma services franchises offer GMP analytical, stability, and CMC testing globally and in Asia-Pacific; it is a deep-pocketed incumbent with the instrumentation partnerships (incl. via its instruments division) that compete for the same Australian sponsor work.
• SGS Life Sciences: SGS operates a global life-sciences testing network including Australian facilities offering GMP release testing, stability, and biopharma analytics; it is a multi-national incumbent against which Pharmalytics competes for pharmaceutical analytical work.

Direct peers

• Pace Analytical Life Sciences: Pace Analytical operates dedicated pharma/biopharma testing labs providing GMP release testing, validation, and stability services to sponsors; it is a US-headquartered CRO peer in the same niche as Pharmalytics but at significantly larger scale.
• IDT Australia: IDT Australia is a Melbourne-based TGA-licensed pharmaceutical contract manufacturer and analytical services provider offering GMP testing and stability services to Australian pharma and biotech; it is a directly comparable Australian CDMO with overlapping analytical capabilities.
• Chemical Analysis Pty Ltd: Founded by Dr. Russell Kinghorn in 2006 and sold in 2018, Chemical Analysis remains a leading Australian contract pharmaceutical testing laboratory offering GMP analytical services; it is the most direct Australian competitor against which Pharmalytics was built, and its successor entity continues to compete for the same clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInau.linkedin.com/company/pharmalyticsaustralia

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmalytics